Ngm Biopharmaceuticals Stock Current Ratio
| NGMDelisted Stock | USD 2.50 0.14 5.30% |
NGM Biopharmaceuticals fundamentals help investors to digest information that contributes to NGM Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of NGM Stock. The fundamental analysis module provides a way to measure NGM Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NGM Biopharmaceutica stock.
NGM |
NGM Biopharmaceuticals Company Current Ratio Analysis
NGM Biopharmaceutica's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current NGM Biopharmaceutica Current Ratio | 7.49 X |
Most of NGM Biopharmaceutica's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NGM Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, NGM Biopharmaceuticals has a Current Ratio of 7.49 times. This is 157.39% higher than that of the Pharmaceuticals sector and 7.0% higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
NGM Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NGM Biopharmaceutica's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NGM Biopharmaceutica could also be used in its relative valuation, which is a method of valuing NGM Biopharmaceutica by comparing valuation metrics of similar companies.NGM Biopharmaceutica is currently under evaluation in current ratio category among its peers.
NGM Fundamentals
| Return On Equity | -0.7 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (179.78) % | |||
| Current Valuation | (36.13 M) | |||
| Shares Outstanding | 83.46 M | |||
| Shares Owned By Insiders | 21.08 % | |||
| Shares Owned By Institutions | 54.16 % | |||
| Number Of Shares Shorted | 1.68 M | |||
| Price To Earning | (21.12) X | |||
| Price To Book | 0.86 X | |||
| Price To Sales | 29.10 X | |||
| Revenue | 4.42 M | |||
| Gross Profit | (125.73 M) | |||
| EBITDA | (144.33 M) | |||
| Net Income | (142.38 M) | |||
| Cash And Equivalents | 297.81 M | |||
| Cash Per Share | 3.71 X | |||
| Total Debt | 5.38 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 7.49 X | |||
| Book Value Per Share | 1.79 X | |||
| Cash Flow From Operations | (132.2 M) | |||
| Short Ratio | 1.26 X | |||
| Earnings Per Share | (1.73) X | |||
| Target Price | 1.66 | |||
| Number Of Employees | 138 | |||
| Beta | 1.26 | |||
| Market Capitalization | 128.53 M | |||
| Total Asset | 168.87 M | |||
| Retained Earnings | (724.01 M) | |||
| Working Capital | 136.36 M | |||
| Current Asset | 330.81 M | |||
| Current Liabilities | 43.69 M | |||
| Net Asset | 168.87 M |
About NGM Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NGM Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NGM Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NGM Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in NGM Stock
If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |